ALT - Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

2024-05-27 07:02:07 ET

Summary

• Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss.
• The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a significant opportunity for Altimmune.
• Altimmune needs to find a partnership to compete with established players like Novo Nordisk and Eli Lilly, but the potential of Pemvidutide is high, making it a buy.

Altimmune Inc. ( ALT ) is completing a Phase 2 clinical trial of pemvidutide , an anti-obesity drug that appears to be able to bring important benefits to weight loss. The differentiating element compared to the competition seems to be the drug's ability to attack 74.5% fat mass and, if confirmed in the next phase 2 and phase 3 steps, could create a competitive moat against already approved drugs that act on the same GLP-1 hormone. The market prospects appear to be very encouraging in terms of current and future growth, so much so that my hypothetical projection of the share price projects it well above $100 in 2030. To proceed on its path, however, Altimmune needs to find an important partnership that allows it to compete on par with the more renowned Novo Nordisk ( NVO ) and Eli Lilly ( LLY ) as well as other players. The potential of the drug, in my opinion, is very important, given the clinical results and market potential, and the chances of success should have a favorable wind. My rate is Buy.

Business Overview

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on one core product called Pemvidutide, designed and developed for the treatment of obesity and liver disease....

For further details see: